MIM
BLCM

Macroview Investment Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Macroview Investment Management’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7
Closed -$1K – 200
2017
Q2 		$1K Buy
+7
New +$869 0.01% 180

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Macroview Investment Management's BLCM Position: Q3 2017 in Review

Macroview Investment Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2017, closing a stake of 7 shares — an estimated $1K sold.

Macroview Investment Management first reported a position in BLCM in Q2 2017 and held it in 1 quarter. The position peaked at $1K in Q2 2017. 88 funds tracked by Wall St. Rank hold BLCM as of Q3 2017.

  • Macroview Investment Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Macroview Investment Management sold 7 Bellicum Pharmaceuticals, Inc. shares in Q3 2017, an estimated $1K.
  • Macroview Investment Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • Macroview Investment Management's Bellicum Pharmaceuticals, Inc. position peaked at $1K in Q2 2017.
  • 88 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2017.

Based on Macroview Investment Management's 13F filing for Q3 2017, filed 30 Oct 2017.